Investors and financial history

Initially created in 2005 with the sole ressources both co-founders brought (100 K€), Neorphys has since obtained loans and subsidies from the Region Languedoc Roussillon, the State and the European Commission, as well as from private entities such as Oséo and Crealia for a total of approximately 1 M€.

A seed financing round has been achieved in march 2007 with venture capital companies Inserm Transfert Initiative and Soridec, then complemented by CEA Investissement in july 2007, to reach a total of 1.050 M€ raised.

Neorphys has then launched an additional road show in 2009 to support the regulatory development of NEO1509, its most advanced visceral pain drug candidate, and to expand its pain pipeline. New investors have joined the syndicate : Fa Diese 2, Seillans Investissement and a number of private business angels. In total, 1.2 M€ have been raised during this new round.

For more details, contact us directly: